1-[(4-chlorophenyl)methyl]-5-methoxy-N-(2-methoxy-4-pyridinyl)-2-methyl-α-oxo-1H-indole-3-acetamide | 1006605-13-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-[(4-chlorophenyl)methyl]-5-methoxy-N-(2-methoxy-4-pyridinyl)-2-methyl-α-oxo-1H-indole-3-acetamide
• 英文别名: 2-(1-(4-chlorobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-(2-methoxypyridin-4-yl)-2-oxoacetamide；2-[1-[(4-chlorophenyl)methyl]-5-methoxy-2-methylindol-3-yl]-N-(2-methoxypyridin-4-yl)-2-oxoacetamide
• CAS: 1006605-13-5
• 化学式: C₂₅H₂₂ClN₃O₄
• 分子量: 463.92
• InChiKey: WPOAHXBKOFOVKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  82.4
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• FAAH INHIBITORS
  申请人：Sprott Kevin

  公开号：US20090118503A1

  公开（公告）日：2009-05-07

  Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.

  本文描述了可用于治疗疼痛、炎症和其他病症的吲哚衍生物。其中某些化合物是苄基衍生物，而其他化合物是苯甲酰基衍生物。这些化合物至少在吲哚的3位被取代。
• INDOLE COMPOUNDS
  申请人：Talley John Jeffrey

  公开号：US20100197708A1

  公开（公告）日：2010-08-05

  Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.

  本文介绍了用于治疗疼痛、炎症和其他疾病的吲哚衍生物。其中某些化合物是苄基衍生物，而其他化合物是苯甲酰基衍生物。这些化合物至少在吲哚的3位被取代。
• Indole compounds
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：EP2610244A1

  公开（公告）日：2013-07-03

  Indole derivatives of formula A that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.

  描述了可用于治疗疼痛、炎症和其他病症的式 A 的吲哚衍生物。其中一些化合物是苄基衍生物，另一些则是苯甲酰基衍生物。这些化合物至少在吲哚的 3 位被取代。
• Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
  申请人：Pearson James Philip

  公开号：US20130150346A1

  公开（公告）日：2013-06-13

  The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors to treat aspects of Parkinson's disease (PD), restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), the use of FAAH inhibitors for the manufacture of medicaments for use in the treatment of PD, RLS and PLMD, as well as pharmaceutically acceptable compositions comprising FAAH inhibitors for use in the treatment of PD, RLS and PLMD.
• Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
  申请人：Pearson James Philip

  公开号：US20130224151A1

  公开（公告）日：2013-08-29

  The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors alone or in combination for the treatment or prevention of abdominal, visceral or pelvic pain. Also described herein are pharmaceutical compositions comprising a FAAH inhibitor, alone or in combination with an additional therapeutic agent for the treatment of abdominal, visceral or pelvic pain.